1 / 37

TB in healthcare workers (HCW) Albert Nienhaus

Institute for Health Service Research for Healthcare Workers (C V care). TB in healthcare workers (HCW) Albert Nienhaus. Leitmotif. 1 WHO Guideline on Latent TB Infection (LTBI). 2 TB risk in HCWs. 3 TST and IGRA in HCWs. 4 Serial testing of HCW. TB-Net for HCWs.

jameskcole
Download Presentation

TB in healthcare workers (HCW) Albert Nienhaus

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Institute for Health Service Research for Healthcare Workers (CVcare) TB in healthcare workers (HCW) Albert Nienhaus

  2. Leitmotif 1 WHO Guideline on Latent TB Infection (LTBI) 2 TB risk in HCWs 3 TST and IGRA in HCWs 4 Serial testing of HCW

  3. TB-Net for HCWs • Register for TB screening in HCWs • 32 physicians contribute data to the register • Pre-employment screening • contact tracing and • repeated testing of HCWs from TB-wards • So far 4,200 HCWs included in the register • Register is financed by the compensation board for HCWs (Berufsgenossenschaft)

  4. Additional sources of data for the presentation I have the honour to collaborate with José Torres Costa, University Clinics Porto, Portugal Dominique Tripodi, University Clinics Nantes, France Paul-Kenneth Gariepy, Hospital St Anne, Paris, France

  5. LTBI WHO 2015 Treatment of LTBI is key to TB elimination in low TB incidence countries

  6. General considerations of the WHO working group • LTBI treatment might result in unwanted side effects • hepatitis • Benefit of treatment must be greater than potential harm • No general screening, no treatment of all LBTI cases • High risk group screening and treatment

  7. Concept of high risk groups LTBI prevalence high low high Progressionrisk low

  8. High risk groups Astrong recommendation • High risk groups: • people living with HIV, • adult and child contacts of pulmonary TB cases, • patients initiating anti-tumor necrosis factor (TNF) treatment, • patients receiving dialysis, • patients preparing for organ or haematologic transplantation, • patients withsilicosis • contradicted by Ringshausen et al Plos one 2013 for German minors. • Testing and treatment of LTBI should be performed

  9. High risk groups Bconditional recommendation • High risk groups B: • prisoners (prison employees), • healthcare workers, • immigrants from high TB burden countries, • homeless persons, • illicit drug users • Testing and treatment of LTBI should be considered depending on national circumstances, recourses, regulations and priorities

  10. Which immunologic test should be used following WHO • TST or IGRA • No recommendation • Populations with BCG vaccination or NTM exposure • not discussed • Reason for (missing) recommendation • Availability of test • (using either test is better than not testing at all) • (Remember: Recommendation for intermediate and high income countries / TB incidence < 100/100,000 countries)

  11. Leitmotif WHO Guideline on Latent TB Infection (LTBI) TB risk in HCWs TST and IGRA in HCWs Serial testing of HCW

  12. Relative Risk for active TB in HCW vs. general population Low TB incidence 2.4 (1.2-3.6) IntermediateTBincidence 2.5 (1.1-3.8) High TB incidence 3.7 (2.4-3.5) Baussano I et al. CDC 2011

  13. case age sex IS6110-DNA-Fingerprint 1 25 m Index 2 68 m ENT-doctor Active TB in a HCW • a waiter from Bali was seen one time for throat problems • 3 weeks later, the waiter was diagnosed with TB • 3 years later, the physician (ENT-doctor) developed TB HamburgFingerprint-Study Diel R et al RespResearch 2005;6:35

  14. Hamburg Fingerprint Study1997 - 2015 based on TB registry in Germany 2,050 patient 41 HCW (2%) cluster 825 (40.2%) nocluster 1,125 (59.8%) HCW no Cluster 19 (46.3%) HCW in Cluster 22 (53.7%) patientto HCW N=12 29.4% HCW to 2 patients N=1 2.4% HCW tofamily N=1 2.4% notransition N=8 19.5% no cluster N=19 46.3% unpublisheddata, courtesy R Diel, S Niemann

  15. TB transmission from HCW to patients? Surprisingly little published evidence 28 reports; transmission rate from HCW with TB to contact 1-5% Schepisi et al 2015: Tuberculosis Transmission from Healthcare Workers to Patients and Co-workers: A Review Plos one 2015 A lot of contacts to be contacted e.g. contact investigation around a healthcare worker (HCW) with infectious TB on a maternity ward in Atlanta in 2013 285 patients who interacted with the HCW Sanderson et al.: J Am Med Inform Assoc. 2015 Sep;22(5):1089-93

  16. Risk of TB infection in HCW Studies using population controls are based on TST Increased risk is well established for low TB incidence, high income countries Seidler et al. 2005; Boussano et al 2011 I am not aware of any study using population controls and IGRA Comparison between HCWs with different probabilities of exposure using IGRA (TB-Net for HCWs) OR 95%CI Lab / Path 2.35 1.4-3.9 Geriatric care 1.98 1.2-3.3 Infection ward 1.76 1.04-3.0 Schablon et al Plos one 2014

  17. latent TB infection (LTBI) preventive treatment (INH) early case detection, isolation and treatment active TB active TB preventive treatment (INH) latent TB infection What do we know about progression risk in HCWs? early case detection, isolation and treatment If finding active TB is unlikely, you might want to find those who will eventually progress to active TB

  18. Progression risk in HCW with positive immunologic test IGRA -TST 1218 Hospital de São João, Porto Torres Costa et al. JOMT 2011 IGRA+/THT+ 371 IGRA+/TST+ 371 IGRA-/THT+ 532 IGRA-/TST+ 532 IGRA-/THT- 289 IGRA-/TST- 289 IGRA+/TST- 26 IGRA+/THT- 26 active TB 0 active TB 0 active TB 8 (2.2%) active TB 0 Progression active TB Progression TB 4 (1%) Progression TB 0 This is below what WHO assumes: IGRA 5%, TST 3%

  19. Different progression rates ? • in general population 12% Diel et al. AJRCCM 2011 • Pooled estimate WHO 5% • in HCWs 1% Torres Costa et al. JOMT 2011 • potential reasons • proportion of old infections in HCWs higher • progression in children higher than in adults • 33% versus 10% in the German progression study • poverty • alcoholism • drug abuse • homelessness

  20. Concept of high risk groups LTBI prevalence high low high Progressionrisk low

  21. Leitmotif WHO Guideline on Latent TB Infection (LTBI) TB risk in HCWs TST and IGRA in HCWs Serial testing of HCW

  22. TST or IGRA ? • Remember: Diagnosis of LTBI • Positive immunologic test and active TB excluded by X-ray • TST + X-ray • TST + IGRA + X-ray • IGRA + X-ray

  23. head to head IGRA und TST Nienhaus et al Pneumologie 2011 X-ray and preventive chemotherapy spared

  24. Effectiveness of TB screening in HCWs? • We know very little about the effectiveness • We have no data to tell us which strategy works best • Cost effectiveness studies of TB screening in HCWs show that screening is cost effective • Two reviews available • Nienhaus et al. JOMT 2011 • Diel, Nienhaus Pharmaco-economics 2015 • IGRA based screening in high risk group is cost-effective • The most recent and most convincing example I know comes from Portugal

  25. TB screening in Portuguese HCWs OSH department inaugurated in 2005 • in 2006 – 2008 • a total of 33 cases of active TB in HCWs • 191 cases / 100,000 HCWs • Relative Risk (RR): 5.99 (95%CI 4.2-8.5) • incidence of TB in HCW decreased because of systematic screening and improved hygiene • Active TB in HCW ( year) • 13 (2006) 14 (2007) 6 (2008) 5 (2009) 2 (2010) 0 (2011) 1 Torres Costa EurRespir J 2009; 34: 1423-1428

  26. TB prevention in healthcare • Early detection of cases • Isolation of smear positive cases • Effective treatment of cases • Mask for patients • Respirator for HCW In addition • TB screening for HCW The ensemble works, the contributions of the single players are unknown

  27. Leitmotif WHO Guideline on Latent TB Infection (LTBI) TB risk in HCWs TST and IGRA in HCWs Serial testing of HCW

  28. Should we repeat IGRA in serial testing of HCW? • Before the advent of IGRA • A positive TST was not repeated • Boosting, strong reaction • Avoid confusion • Once positive in TST, X-ray in routine screening ever after • LTBI was considered a stable state (and its variability forgotten) • High reversion rate in IGRA • was a surprise • ? reversers do not need X-ray? (This is a big advantage for those HCWs pertaining to repeated screening schemas)

  29. TNFα control LTBI is an unstable state Active TB Transient infection 8 weeks Dormant state Local reaction lung TB granuloma (LTBI) Low replication with T cell stimulation Uncontrolled replication Subclinical or clinical TB

  30. When analyzing the same tube twice • Concordance of the results >98 % • but variation of the concentration (30 % of the mean) • For results close to the cut-off, this might cause problems, • otherwise this is no problem but a scientific challenge

  31. Reversion and risk of LTBI • Specificity of test 95 %, sensitivity 100 % • Risk of LTBI 2 % 10 % 50 % • Expected positive 2+5 10+4.5 50+5 • Expected reversion >50% 30% <10% • Country US Germany South Africa

  32. Reversion in TST and QFT QFT positive 2,761 (52 %) Reversion 4.3 – 5.7 %

  33. Reversion in TST and QFT QFT positive 2,761 (52 %) Reversion 4.3 – 5.7 % TST positive 2,987 (56 %) Reversion 3.8 – 4.5 %

  34. Risk factors for conversion of QFTin 3582 HCWs noinfluenceofageandgender

  35. Risk factors for reversion in 640 HCW noinfluenceofageandgender HCWs with a reversioncango back intothe IGRA screeningpool

  36. Do we need a borderline zone? • The data suggest to use a borderline zone • 0.2 – 0.7 IU/ml • in groups with no recent exposure and low progression risk • Let‘s be careful in exposed groups

  37. TB in Portuguese HCW Nienhaus and Torres Costa JOMT 2013

More Related